Lansoprazol Stada (Lansoprazole)

Lansoprazole is a proton pump inhibitor used to reduce gastric acid production in several acid‑related disorders.

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by lowering stomach acid.
• Peptic ulcer disease: promotes healing of gastric and duodenal ulcers through acid suppression.
• NSAID‑induced ulcer prophylaxis: prevents ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs.
• Helicobacter pylori eradication: used in combination therapy to increase eradication rates of H. pylori infection.

• Lansoprazole selectively and irreversibly inhibits the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, providing an environment conducive to ulcer healing and symptom relief.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate pain often resolving without intervention.
• Diarrhea: loose stools that may be transient.
• Nausea: feeling of queasiness, sometimes accompanied by vomiting.
• Abdominal pain: discomfort or cramping in the stomach area.
• Flatulence: increased gas production.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing.
• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Low magnesium levels (hypomagnesemia): muscle cramps, seizures, arrhythmias.
• Liver enzyme elevation: signs of hepatitis, jaundice.
• Interstitial nephritis: kidney inflammation causing reduced function.
• Stevens‑Johnson syndrome: serious skin and mucous membrane disorder.

Before initiating therapy with Lansoprazol Stada, consider the following precautions.

• Renal function assessment: adjust use in patients with severe kidney impairment.
• Hepatic impairment: use with caution in patients with liver disease.
• Magnesium monitoring: check serum magnesium during prolonged treatment.
• Rebound acid hypersecretion: avoid abrupt discontinuation after long‑term use.
• Potential drug interactions: review concomitant medications for CYP2C19 substrates.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Lansoprazol Stada may interact with several medications; categorisation guides clinical management.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect.
• Atazanavir: decreased antiviral absorption.
• HIV protease inhibitors (e.g., ritonavir): altered plasma concentrations.
• Methotrexate: increased toxicity risk.
• Warfarin: unpredictable anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Digoxin: increased serum levels.
• Phenytoin: reduced phenytoin concentrations.
• Phenobarbital: decreased efficacy of both drugs.
• Ketoconazole: altered antifungal exposure.
• Fluconazole: potential increase in lansoprazole levels.